fasudil has been researched along with Limb-Girdle Muscular Dystrophies in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil treated SJL/J mice showed increased body weight, but decreased grip strength, horizontal activity, and soleus muscle force, compared to untreated SJL/J controls." | 1.36 | Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. ( Gordish-Dressman, H; Hoffman, EP; Knoblach, SM; Nagaraju, K; Rayavarapu, S; Van der Meulen, JH, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rayavarapu, S | 1 |
| Van der Meulen, JH | 1 |
| Gordish-Dressman, H | 1 |
| Hoffman, EP | 1 |
| Nagaraju, K | 1 |
| Knoblach, SM | 1 |
1 other study available for fasudil and Limb-Girdle Muscular Dystrophies
| Article | Year |
|---|---|
Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Drug Evaluation, Pre | 2010 |